Education
About Us
Working with TipRanks
Follow Us
Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
SCNI Stock Chart & Stats
$0.78
-$0.11(-3.01%)
At close: 4:00 PM EST
$0.78
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$0.61 - $6.18
Previous CloseN/A
Volume8.73K
Average Volume (3M)101.31K
Market Cap
$634.97K
Enterprise Value$2.35M
Total Cash (Recent Filing)$989.00K
Total Debt (Recent Filing)$2.36M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.74
Shares Outstanding3,187,679
10 Day Avg. Volume127,573
30 Day Avg. Volume101,310
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.27
Price to Sales (P/S)4.11
P/FCF Ratio-0.43
Enterprise Value/Market Cap3.69
Enterprise Value/Revenue2.05
Enterprise Value/Gross Profit-1.39
Enterprise Value/Ebitda0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet ImprovementThe shift to positive equity and lower leverage in 2024 materially strengthens financial flexibility versus prior years. This improved capital structure provides a longer runway for R&D and operations, reducing near-term refinancing pressure and lowering the probability of forced dilutive raises.
CDMO/business Diversification Driving RevenueExpansion of Scinai Bioservices and CDMO revenue creates a recurring, services-based cash stream distinct from volatile drug milestones. Structural diversification into manufacturing and CDMO reduces dependence on single-candidate outcomes and supports steadier revenue and capacity investments over the medium term.
Shareholder-backed Governance & Strategic FlexibilityShareholder approval of governance changes and authorization for additional shares gives management strategic flexibility to incentivize leadership, structure long-term compensation, and access capital when needed. Endorsement of auditor and leadership supports continuity during restructuring.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicate the company continues to consume cash to fund R&D and operations. Over multiple years this creates reliance on external financing, increasing dilution risk and constraining the ability to invest opportunistically without consistent positive cash generation.
Negative Core ProfitabilityDeep negative gross profit and large operating losses show core operations are not yet structurally profitable. Reported net income gains appear driven by non-operational items, so without structural margin improvement the company will struggle to convert revenue growth into sustainable earnings or self-funded R&D.
Historic Leverage And Dilution RiskAlthough 2024 improved, the prior pattern of extreme leverage and negative equity highlights a recurring financing vulnerability. If losses persist, the company may again face high cost capital, frequent equity raises, or restrictive covenants, raising long-term dilution and execution risk for programs.
Scinai Immunotherapeutics News
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $0.61 and its highest was $6.18 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is $634.97K.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is May 07, 2026 which is in 80 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Dec 02, 2025. The company reported -$4.742 earnings per share for the quarter, missing the consensus estimate of N/A by -$4.742.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 3,187,679 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of -$4.742 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Technical Analysis
GT Biopharma
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Conduit Pharmaceuticals
―
Ownership Overview
―
Insiders
0.46% Other Institutional Investors
99.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---